Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

BELLUS Health Inc BLUSD


Primary Symbol: T.BLU

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.


TSX:BLU - Post by User

Bullboard Posts
Comment by ichibanichiban9on Jul 09, 2016 2:52pm
259 Views
Post# 25038334

RE:RE:ANSWER OS BELLUS...

RE:RE:ANSWER OS BELLUS...The alzehimer drug trials of Tramiprosate is what you are referring to is now close to starting Ph 3 at a company called Alzheon. Run by Martin Tolar(a Bellus director) and supported by a team of some of the very best in neurology/ alzheimers.Bellus sold the rights and data set of the Tramiprosate trials to Alzheon for future royalties. Look up Alzheon and see what the data from the previous drug trials have revealed. It is invaluable information for future drug development. Failed drug trials, while painful to all involved, are not the end. If any of you understand the world of drug discovery you will understand this is not easy, it is not fast and it is certainly not cheap.
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse